Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer
- Authors
- Kwon, Jung Hye; Nam, Seung-Hyun; Koh, Sujin; Hong, Young Seon; Lee, Kyung Hee; Shin, Sang-Won; Hui, David; Park, Kyun Woo; Yoon, So Young; Won, Ji Yun; Chisholm, Gary; Bruera, Eduardo
- Issue Date
- 12월-2013
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Advanced cancer; Edmonton Symptom Assessment System; ESAS; Korea
- Citation
- JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, v.46, no.6, pp.947 - 956
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Volume
- 46
- Number
- 6
- Start Page
- 947
- End Page
- 956
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/101475
- DOI
- 10.1016/j.jpainsymman.2013.01.012
- ISSN
- 0885-3924
- Abstract
- Context. The Edmonton Symptom Assessment System (ESAS) is a brief, widely adopted, multidimensional questionnaire to evaluate patient-reported symptoms. Objectives. To develop a Korean version of the ESAS (K-ESAS) and to perform a psychometric analysis in Korean patients with advanced cancer. Methods. We tested the K-ESAS in two pilot studies with 15 patients each. We assessed internal consistency, test-retest reliability, and concurrent validity in 163 Korean patients, who completed the K-ESAS along with the Korean versions of the M. D. Anderson Symptom Inventory (K-MDASI) and the Hospital Anxiety and Depression Scale (K-HADS) twice. A total of 38 patients completed the questionnaires again seven days later to assess responsiveness. Results. The K-ESAS scores had good internal consistency, with a Cronbach's alpha coefficient of 0.88, indicating that no questions had undue influence on the score. Pearson correlation coefficients for K-ESAS symptom scores between baseline and after two to four hours ranged from 0.72 (95% CI 0.64-0.79) to 0.87 (95% CI 0.82-0.90), indicating strong test-retest reliability. For concurrent validity, Pearson correlation coefficients between K-ESAS symptom scores and corresponding K-MDASI symptom scores ranged from 0.70 (95% CI 0.62-0.77) to 0.83 (95% CI 0.77-0.87), indicating good concurrent validity. For the K-HADS, concurrent validity was good for anxiety (r = 0.73, 95% CI 0.65-0.79) but moderate for depression (r = 0.4, 95% CI 0.26-0.52). For responsiveness, changes in K-ESAS scores after seven days were moderately correlated with changes in K-MDASI scores but weakly correlated with changes in K-HADS scores. Conclusion. The K-ESAS is a valid and reliable tool for measuring multidimensional symptoms in Korean patients with cancer. (C) 2013 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.